Breast cancer with positive HER-2 status was associated with an increased risk of developing LRR in comparison with negative HER-2 status (HR 1.65, 95% CI: 1.06–2.58, P=0.027, Figure 5). This evidence concerns the gene ERBB2 and breast cancer.